The Latest Breaking News from GH

We take a look at the best websites to visit if you want to treat your mum to a bouquet delivered to her door

Guardant unveiled results for its colon cancer-detecting blood test that lagged rival Exact. GH stock crashed as EXAS stock jumped Friday.

U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

With newly arriving health care staff struggling to find accommodation in Horsham, Grampians Health unveils plans to build a local housing development for staff.

Tamil Nadu government orders probe; CM Stalin announces ₹5 lakh solatium

The oncology industry is expected to grow considerably in 2022, driven by the rising occurrence of cancer in the U.S. population. Furthermore, increasing investments by biopharmaceutical companies and the government should fuel the industry's growth. Given the industry's bright growth prospects, Wall Street analysts expect the stocks of quality oncology…

A quack offered to determine the sex of the foetus and abort it

Guardant Health Inc's (NASDAQ:GH) Q1 FY22 revenues rose 22% Y/Y to $96.1 million, beating the consensus of $95.70 million. Guardant's precision oncology testing revenues grew 32% to $84.1 million, driven by the increase in clinical and biopharma testing.  Development services and other revenues rose 20% to $12.0 million from $14.9 million in…

According to data from Benzinga Pro, during Q4, Guardant Health's (NASDAQ:GH) reported sales totaled $108.11 million. Despite a 32.75% increase in earnings, the company posted a loss of $72.31 million.

Guardant Health (NASDAQ:GH) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:03 PM. Here's what investors need to know about the announcement.